Plus Therapeutics Inc.
06/17/2025 | Press release | Distributed by Public on 06/17/2025 14:25
Material Agreement, Corporate Action (Form 8-K)
| Item 1.01 |
Entry into a Material Definitive Agreement. |
As previously disclosed, on March 4, 2025, Plus Therapeutics, Inc. (the "Company") entered into that certain Securities Purchase Agreement, dated March 4, 2025 (the "Purchase Agreement"), with the various purchasers party thereto (the "Purchasers"), pursuant to which the Company issued to such Purchasers in an private placement (the "March 2025 Private Placement") the following securities of the Company: (i) an aggregate of 4,069,738 shares (the "Private Placement Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock"), (ii) prefunded warrants (the "Pre-FundedWarrants") to purchase an aggregate of up to 23,972,400 shares of Common Stock (the "Prefunded Warrant Shares"), (iii) Series A Warrants (the "Series A Warrants") to purchase up to an aggregate of 280,421,380 shares of Common Stock (assuming full adjustment based on the floor price specified in the Series A Warrants) (the "Series A Warrant Shares"), and (iv) Series B Warrants (the "Series B Warrants") to purchase up to an aggregate of 1,261,896,210 shares of Common Stock (assuming full adjustment based on the floor price specified in the Series B Warrants and accounting for the alternative cashless exercise feature of 3:1 contained therein) (the "Series B Warrant Shares").
On June 17, 2025, the Company and the Purchasers entered into a letter agreement (the "Letter Agreement") with each of the Purchasers in an effort to, among other items, minimize the dilutive impact of the March 2025 Private Placement. Pursuant to the Letter Agreement:
| • |
Cancellation of Series AWarrants. The Company and each of the Purchasers agreed to terminate all Series A Warrants in full. |
| • |
Amendment of Series B Warrants. The Company and each of the Purchasers agreed to amend all outstanding Series B Warrants in the form of Exhibit 4.1 hereto (the "Amended Series B Warrants") to (a) reduce the overall number of Series B Warrant Shares issuable upon exercise of the Series B Warrants to an aggregate of up to 35,536,380 Series B Warrant Shares, (b) reduce the alternative cashless exercise ratio in such Series B Warrants from 3:1 to 1:1, and (c) remove provisions contained in the Series B Warrants that would otherwise reduce the Company's stockholders' equity. |
| • |
Waiver of Registration Rights Agreement. The Company and each of the Purchasers agreed to terminate the Registration Rights Agreement and nullify all past, present and future obligations with respect thereto. |
| • |
Return of Private Placement Shares and Pre-FundedWarrants. Each of the Purchasers agreed to return an aggregate of 12,241,986 Private Placement Shares and Pre-FundedWarrants issuable for an aggregate of 10,633,650 Pre-FundedWarrant Shares, held by them as of the date of the Letter Agreement, upon request of the Company, which were issued pursuant to the Purchase Agreement for a value of $0.66 per Private Placement Share and $0.659 per Pre-FundedWarrant. In exchange therefore, the Company agreed to repay the Purchasers holding such securities 115% of such value, using 90% of the proceeds from any capital raised by the Company subsequent to July 1, 2025. The Company and each of the Purchasers also agreed to waive any restrictions on subsequent equity sales and variable rate transactions contained in Purchase Agreement to allow for such repayment. |
The foregoing descriptions of the Letter Agreements and A&R Series B Warrants are qualified in their entirety by reference to the full text of such documents, copies of which are attached hereto as exhibits, and each of which is incorporated herein by reference.
| Item 3.03 |
Material Modification to Rights of Security Holders. |
To the extent required, the information contained in Item 1.01 above is incorporated herein by reference.
Plus Therapeutics Inc. published this content on June 17, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 17, 2025 at 20:25 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io